Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2025)
Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

Industry: Biotechnology
F
Biotech is Zen Rated F and is the 137th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
AUPH
AURINIA PHARMACEUTICALS INC
$1.01BN/A0.00%N/AN/AN/AN/A
EXEL
EXELIXIS INC
$11.90BN/A0.00%N/AN/AN/AN/A
INCY
INCYTE CORP
$13.30BN/A0.00%N/AN/AN/AN/A
HALO
HALOZYME THERAPEUTICS INC
$6.52BN/A0.00%N/AN/AN/AN/A
CPRX
CATALYST PHARMACEUTICALS INC
$2.58BN/A0.00%N/AN/AN/AN/A
PTCT
PTC THERAPEUTICS INC
$3.85BN/A0.00%N/AN/AN/AN/A
PBYI
PUMA BIOTECHNOLOGY INC
$178.20MN/A0.00%N/AN/AN/AN/A
NAGE
NIAGEN BIOSCIENCE INC
$1.01BN/A0.00%N/AN/AN/AN/A
RIGL
RIGEL PHARMACEUTICALS INC
$334.39MN/A0.00%N/AN/AN/AN/A
BMRN
BIOMARIN PHARMACEUTICAL INC
$10.78BN/A0.00%N/AN/AN/AN/A
CRMD
CORMEDIX INC
$799.65MN/A0.00%N/AN/AN/AN/A
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$1.84BN/A0.00%N/AN/AN/AN/A
CSBR
CHAMPIONS ONCOLOGY INC
$99.69MN/A0.00%N/AN/AN/AN/A
BCRX
BIOCRYST PHARMACEUTICALS INC
$1.88BN/A0.00%N/AN/AN/AN/A
INVA
INNOVIVA INC
$1.24BN/A0.00%$0.2500N/AN/A0
PLX
PROTALIX BIOTHERAPEUTICS INC
$117.82MN/A0.00%N/AN/AN/AN/A
ALNY
ALNYLAM PHARMACEUTICALS INC
$41.99BN/A0.00%N/AN/AN/AN/A
THTX
THERATECHNOLOGIES INC
$105.75MN/A0.00%N/AN/AN/AN/A
BDTX
BLACK DIAMOND THERAPEUTICS INC
$141.02MN/A0.00%N/AN/AN/AN/A
NVO
NOVO NORDISK A S
$311.75B2.31%45.20%$1.0992$1.6151%10
AKBA
AKEBIA THERAPEUTICS INC
$937.61MN/A0.00%N/AN/AN/AN/A
ZVRA
ZEVRA THERAPEUTICS INC
$489.38MN/A0.00%N/AN/AN/AN/A
MDXG
MIMEDX GROUP INC
$918.71MN/A0.00%N/AN/AN/AN/A
TBPH
THERAVANCE BIOPHARMA INC
$545.51MN/A0.00%N/AN/AN/AN/A
ARWR
ARROWHEAD PHARMACEUTICALS INC
$2.22BN/A0.00%N/AN/AN/AN/A
HRTX
HERON THERAPEUTICS INC
$331.06MN/A0.00%N/AN/AN/AN/A
KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
$1.99BN/A0.00%N/AN/AN/AN/A
IMCR
IMMUNOCORE HOLDINGS PLC
$1.65BN/A0.00%N/AN/AN/AN/A
ONC
BEONE MEDICINES LTD
$26.49BN/A0.00%N/AN/AN/AN/A
XLO
XILIO THERAPEUTICS INC
$35.89MN/A0.00%N/AN/AN/AN/A
MIRM
MIRUM PHARMACEUTICALS INC
$2.40BN/A0.00%N/AN/AN/AN/A
MNKD
MANNKIND CORP
$1.09BN/A0.00%N/AN/AN/AN/A
ZLAB
ZAI LAB LTD
$3.82BN/A0.00%N/AN/AN/AN/A
GMAB
GENMAB A
$13.73BN/A0.00%N/AN/AN/AN/A
XOMA
XOMA ROYALTY CORP
$315.21MN/A0.00%N/AN/AN/AN/A
VCYT
VERACYTE INC
$2.14BN/A0.00%N/AN/AN/AN/A
FENC
FENNEC PHARMACEUTICALS INC
$229.24MN/A0.00%N/AN/AN/AN/A
IMAB
I-MAB
$191.04MN/A0.00%N/AN/AN/AN/A
STOK
STOKE THERAPEUTICS INC
$636.05MN/A0.00%N/AN/AN/AN/A
VRNA
VERONA PHARMA PLC
$7.70BN/A0.00%N/AN/AN/AN/A
TARS
TARSUS PHARMACEUTICALS INC
$1.68BN/A0.00%N/AN/AN/AN/A
RPRX
ROYALTY PHARMA PLC
$20.17B1.81%34.40%$0.2200$0.6540%0
ACAD
ACADIA PHARMACEUTICALS INC
$3.57BN/A0.00%N/AN/AN/AN/A
ATRA
ATARA BIOTHERAPEUTICS INC
$46.50MN/A0.00%N/AN/AN/AN/A
VRTX
VERTEX PHARMACEUTICALS INC
$116.11BN/A0.00%N/AN/AN/AN/A
UTHR
UNITED THERAPEUTICS CORP
$13.12BN/A0.00%N/AN/AN/AN/A
TGTX
TG THERAPEUTICS INC
$5.62BN/A0.00%N/AN/AN/AN/A
XERS
XERIS BIOPHARMA HOLDINGS INC
$746.32MN/A0.00%N/AN/AN/AN/A
TECH
BIO-TECHNE CORP
$8.16B0.61%38.60%$0.0800$0.3212%1
CORT
CORCEPT THERAPEUTICS INC
$7.35BN/A0.00%N/AN/AN/AN/A
ZYME
ZYMEWORKS INC
$864.77MN/A0.00%N/AN/AN/AN/A
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$1.64BN/A0.00%N/AN/AN/AN/A
ARGX
ARGENX SE
$32.96BN/A0.00%N/AN/AN/AN/A
WHWK
WHITEHAWK THERAPEUTICS INC
$87.62MN/A0.00%N/AN/AN/AN/A
FTRE
FORTREA HOLDINGS INC
$468.90MN/A0.00%N/AN/AN/AN/A
KROS
KEROS THERAPEUTICS INC
$541.81MN/A0.00%N/AN/AN/AN/A
CTMX
CYTOMX THERAPEUTICS INC
$190.27MN/A0.00%N/AN/AN/AN/A
ADPT
ADAPTIVE BIOTECHNOLOGIES CORP
$1.70BN/A0.00%N/AN/AN/AN/A
LGND
LIGAND PHARMACEUTICALS INC
$2.17BN/A0.00%N/AN/AN/AN/A
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$3.39BN/A0.00%N/AN/AN/AN/A
SPRO
SPERO THERAPEUTICS INC
$162.14MN/A0.00%N/AN/AN/AN/A
RGNX
REGENXBIO INC
$412.82MN/A0.00%N/AN/AN/AN/A
NTRB
NUTRIBAND INC
$89.46MN/A0.00%N/AN/AN/AN/A
FHTX
FOGHORN THERAPEUTICS INC
$271.46MN/A0.00%N/AN/AN/AN/A
IPSC
CENTURY THERAPEUTICS INC
$46.78MN/A0.00%N/AN/AN/AN/A
SEER
SEER INC
$128.92MN/A0.00%N/AN/AN/AN/A
AGEN
AGENUS INC
$132.70MN/A0.00%N/AN/AN/AN/A
ACOG
ALPHA COGNITION INC
$147.38MN/A0.00%N/AN/AN/AN/A
MCRB
SERES THERAPEUTICS INC
$93.48MN/A0.00%N/AN/AN/AN/A
GLUE
MONTE ROSA THERAPEUTICS INC
$283.56MN/A0.00%N/AN/AN/AN/A
SEPN
SEPTERNA INC
$472.32MN/AN/AN/AN/AN/AN/A
TRAW
TRAWS PHARMA INC
$8.12MN/A0.00%N/AN/AN/AN/A
NVAX
NOVAVAX INC
$1.07BN/A0.00%N/AN/AN/AN/A
MESO
MESOBLAST LTD
$1.40BN/A0.00%N/AN/AN/AN/A
CADL
CANDEL THERAPEUTICS INC
$243.00MN/A0.00%N/AN/AN/AN/A
ACIU
AC IMMUNE SA
$198.81MN/A0.00%N/AN/AN/AN/A
TSHA
TAYSHA GENE THERAPIES INC
$502.31MN/A0.00%N/AN/AN/AN/A
TVTX
TRAVERE THERAPEUTICS INC
$1.31BN/A0.00%N/AN/AN/AN/A
KRYS
KRYSTAL BIOTECH INC
$4.02BN/A0.00%N/AN/AN/AN/A
TVRD
TVARDI THERAPEUTICS INC
$207.34MN/A0.00%N/AN/AN/AN/A
AEON
AEON BIOPHARMA INC
$9.01MN/A0.00%N/AN/AN/AN/A
IONS
IONIS PHARMACEUTICALS INC
$6.36BN/A0.00%N/AN/AN/AN/A
ATAI
ATAI LIFE SCIENCES NV
$542.91MN/A0.00%N/AN/AN/AN/A
TLX
TELIX PHARMACEUTICALS LTD
$5.38BN/AN/AN/AN/AN/AN/A
MDGL
MADRIGAL PHARMACEUTICALS INC
$6.66BN/A0.00%N/AN/AN/AN/A
GYRE
GYRE THERAPEUTICS INC
$699.43MN/A0.00%$20.0200N/AN/A0
SLS
SELLAS LIFE SCIENCES GROUP INC
$207.54MN/A0.00%N/AN/AN/AN/A
KYMR
KYMERA THERAPEUTICS INC
$2.89BN/A0.00%N/AN/AN/AN/A
ITOS
ITEOS THERAPEUTICS INC
$382.74MN/A0.00%N/AN/AN/AN/A
ABVC
ABVC BIOPHARMA INC
$40.59MN/A0.00%N/AN/AN/AN/A
FOLD
AMICUS THERAPEUTICS INC
$1.80BN/A0.00%N/AN/AN/AN/A
ANIX
ANIXA BIOSCIENCES INC
$104.04MN/A0.00%N/AN/AN/AN/A
VYNE
VYNE THERAPEUTICS INC
$29.50MN/A0.00%N/AN/AN/AN/A
CNTA
CENTESSA PHARMACEUTICALS PLC
$1.76BN/A0.00%N/AN/AN/AN/A
FULC
FULCRUM THERAPEUTICS INC
$369.22MN/A0.00%N/AN/AN/AN/A
HLVX
HILLEVAX INC
$101.28MN/A0.00%N/AN/AN/AN/A
ASMB
ASSEMBLY BIOSCIENCES INC
$135.41MN/A0.00%N/AN/AN/AN/A
ASND
ASCENDIS PHARMA A
$10.44BN/A0.00%N/AN/AN/AN/A
YMAB
Y-MABS THERAPEUTICS INC
$199.70MN/A0.00%N/AN/AN/AN/A
REGN
REGENERON PHARMACEUTICALS INC
$57.75B0.33%2.10%$0.8800$1.765%0

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Jul 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

1. Aurinia Pharmaceuticals (NASDAQ:AUPH)


Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #1 top biotech stock out of 651 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 65, which is 41 points higher than the biotech industry average of 24.

AUPH passed 21 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 36.25% over the past year, overperforming other biotech stocks by 109 percentage points.

2. Exelixis (NASDAQ:EXEL)


Exelixis (NASDAQ:EXEL) is the #2 top biotech stock out of 651 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Exelixis (NASDAQ:EXEL) is: Value: A, Growth: C, Momentum: C, Sentiment: A, Safety: C, Financials: A, and AI: C.

Exelixis (NASDAQ:EXEL) has a Due Diligence Score of 60, which is 36 points higher than the biotech industry average of 24.

EXEL passed 20 out of 33 due diligence checks and has strong fundamentals. Exelixis has seen its stock return 96.04% over the past year, overperforming other biotech stocks by 168 percentage points.

Exelixis has an average 1 year price target of $43.80, an upside of 0.41% from Exelixis's current stock price of $43.62.

Exelixis stock has a consensus Buy recommendation according to Wall Street analysts. Of the 15 analysts covering Exelixis, 40% have issued a Strong Buy rating, 20% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the #3 top biotech stock out of 651 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Incyte (NASDAQ:INCY) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: C, Financials: B, and AI: B.

Incyte (NASDAQ:INCY) has a Due Diligence Score of 47, which is 23 points higher than the biotech industry average of 24.

INCY passed 15 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock return 12.91% over the past year, overperforming other biotech stocks by 85 percentage points.

Incyte has an average 1 year price target of $75.00, an upside of 9.12% from Incyte's current stock price of $68.73.

Incyte stock has a consensus Hold recommendation according to Wall Street analysts. Of the 10 analysts covering Incyte, 20% have issued a Strong Buy rating, 0% have issued a Buy, 80% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Dominari Holdings (NASDAQ:DOMH)


Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 6.06%, which is 4 percentage points higher than the biotech industry average of 1.59%.

Dominari Holdings's dividend payout ratio of -7.1% indicates that its high dividend yield might not be sustainable for the long-term.

2. Novo Nordisk (Ozempic) (NYSE:NVO)


Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.31%, which is 1 percentage points higher than the biotech industry average of 1.59%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 45.2% indicates that its dividend yield is sustainable for the long-term.

3. Royalty Pharma (NASDAQ:RPRX)


Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 1.81%, which is the same as the biotech industry average of 1.59%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 34.4% indicates that its dividend yield is sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 0.06% in the last day, and down -1.7% over the last week. Mustang Bio was the among the top gainers in the biotechnology industry, gaining 114.66% yesterday.

Mustang Bio shares are trading higher after the company announced it received FDA Orphan Drug designation status for MB-101.

What are the most undervalued biotech stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

1. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 5.29% in the past year. It has overperformed other stocks in the biotech industry by 78 percentage points.

2. Puma Biotechnology (NASDAQ:PBYI)


Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 9.45% in the past year. It has overperformed other stocks in the biotech industry by 82 percentage points.

3. United Therapeutics (NASDAQ:UTHR)


United Therapeutics (NASDAQ:UTHR) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

United Therapeutics has a valuation score of 43, which is 28 points higher than the biotech industry average of 15. It passed 3 out of 7 valuation due diligence checks.

United Therapeutics's stock has dropped -8.81% in the past year. It has overperformed other stocks in the biotech industry by 64 percentage points.

Are biotech stocks a good buy now?

53.4% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 105.42% over the next year.

2.36% of biotech stocks have a Zen Rating of A (Strong Buy), 4.07% of biotech stocks are rated B (Buy), 37.69% are rated C (Hold), 35.33% are rated D (Sell), and 20.56% are rated F (Strong Sell).

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is -123.2x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.